All News

RheumNow Podcast square

Prelude to a Meeting (ACR22) (11.11.2022)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.

Read Article
syringe, pill, DMARD, Treatment, therapy

Emerging and exciting treatments in RA: ACR22 preview

d Julian Segan, MBBS, BMedSc, FRACP

Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.

Read Article
RA, hands, MCP, deformity

New 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis

d Jack Cush, MD

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.

Read Article
Convention2.jpg

AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22

d Robert Chao, MD

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.

Read Article
Dr. Coldiron (thru case examples) shares how the MSF works in providing medical care to pts in areas of conflict or crisis & how #climate change has also impacted health, including #Mentalhealth #ACR22 @RheumNow @rheumarhyme https://t.co/gFuX4sL0WA
sheila RHEUMarampa ( View Tweet)
50 yo hispanic male +MDA5 Ab w/ synovitis, skin lesions, neg ANA, normal CK, aldolase, +MDA5 Ab, Skin biopsy show changes c/w dermatomyositis. Failed MTX/MMF, no insurance. What is MDA5's role? Does race play a factor in Rx response? What is your next step? @rheumnow #ACR22 https://t.co/tGy2BH6y45
TheDaoIndex KDAO2011 ( View Tweet)
Dr. R Puligari: 55 yo female w/arthritis, rash, DOE, fever, weight loss, CT abnormal +MDA5 dermatomyositis: Rx RTX, IV steroids, CYP, TAC and Ofev. Disease progressed; IVIG,steroids, PLEX added w/benefits. 6 months later had CMV retinitis. What to do next? #ACR22 @rheumnow https://t.co/A1m8HMtCob
TheDaoIndex KDAO2011 ( View Tweet)
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Dr. M Tikly share #rheum challenges & solutions in South Africa: 👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics 👉lobby local government/political groups 👉use of off-label drugs 👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇 🔸Off label use, buyouts, price⬇️, advocacy... Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging #ACR22 @rheumnow https://t.co/ajshylgtIE
sheila RHEUMarampa ( View Tweet)
Finally we're starting to get therapies for polymyalgia rheumatica! The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
David Liew drdavidliew ( View Tweet)
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs. https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s

Links:

Dr. John Cush RheumNow ( View Tweet)
Update: axSpA Recommendations https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 78 824 adults shows Prevalence of Cannabis use was significantly higher during the pandemic vs before the pandemic in states where it is legalized (but not increase in nonlegal states) esp in adults 18 to 29 and 30 to 54 years https://t.co/ZZzCl7dstj https://t.co/qbQLPhI6I8

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Yuz Yusof will be covering #ACR22 as a RheumNow reporter again. He'll be sharing real-time coverage on SLE, auto-inflammatory and COVID. Follow @Yuz6Yusof! https://t.co/3rYlIrM54m
Dr. John Cush RheumNow ( View Tweet)
Chronic Pain increased from 2010-2919. A cross-sectional study of 46 420 respondents, shows nonpharmacologic Rx increased [aOR 2.72] & was greater than opioids for chronic, but not surgical pain. Govt policy & practice guidelines have helped. https://t.co/31oS0xWRMW https://t.co/IvkDRJQvT8

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep Habits study from NHANES - 9004 adults >20 yrs (2017-2020) finds mean sleep duration 7.6 hrs on workdays & 8.2 hrs on free days; 23% slept <7 hrs & 25% went to bed > midnight. Nearly 30% had trouble sleeping (daytime sleepiness 27%) https://t.co/Uc7nL4q3fm https://t.co/qvCwqbsez1

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow RheumNow reporter, Dr. Eric Dein, for real-time #ACR22 coverage! https://t.co/NZkVd2A989
Dr. John Cush RheumNow ( View Tweet)
Our newest RheumNow reporter, Dr. Michael Putman , will be covering SLE and Vasculitis at #ACR22 this year. “Looking forward to seeing all my friends and colleagues in person!”-Dr. Putnam Follow him @EBRheum for real-time coverage! https://t.co/DpFa0zwzPX
Dr. John Cush RheumNow ( View Tweet)
×